SillaJen, Inc (215600) Fair Value & Analysis
Healthcare · KR · Market cap 358B KRW
Fair value as of: Jun 24, 2026
Analysis
SillaJen, Inc (215600) currently trades at 2,415 KRW, while our model-based Fair Value estimate is 3,588 KRW — implying the stock looks roughly 48.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is SillaJen, Inc (215600) undervalued?
What is the fair value of 215600?
What is the quality score of 215600?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.